Search

Displaying results 3131 - 3140 of 10000 in total
  1. Drug

    Iseganan

    go.drugbank.com/drugs/DB16010
    Investigational

    Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).

    Categories: Pore Forming Cytotoxic Proteins
  2. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    Amyl Nitrite

    go.drugbank.com/drugs/DB01612
    Approved

    Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use.

  4. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

    Products: Cimalgex 30mg chewable tablets for dogs, Cimalgex 80mg chewable tablets for dogs
  5. Drug

    Queuine

    go.drugbank.com/drugs/DB14732
    ExperimentalNutraceutical

    Humans salvage and recover queuine from either ingested food or the gut flora. … Queuine is a derivative of [7-Deazaguanine]. Bacteria possess the exclusive ability to synthesize queuine, which is then salvaged and passed on to plants and animals.

  6. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. … Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received

  7. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). … [A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.

  8. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma

  9. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion

  10. Drug

    CXD101

    go.drugbank.com/drugs/DB16182
    Investigational

    CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).